4-Bromo-2-(methylsulfonamido)benzoic acid → N-{5-bromo-2-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]phenyl}methanesulfonamide
Reaktionsgleichung
[Br:1][C:2]1[CH:10]=[CH:9][C:5]([C:6]([OH:8])=O)=[C:4]([NH:11][S:12]([CH3:15])(=[O:14])=[O:13])[CH:3]=1.[CH3:16][C:17]1[C:18]([N:24]2[CH2:29][CH2:28][NH:27][CH2:26][CH2:25]2)=[N:19][CH:20]=[C:21]([CH3:23])[CH:22]=1>>[Br:1][C:2]1[CH:10]=[CH:9][C:5]([C:6]([N:27]2[CH2:28][CH2:29][N:24]([C:18]3[C:17]([CH3:16])=[CH:22][C:21]([CH3:23])=[CH:20][N:19]=3)[CH2:25][CH2:26]2)=[O:8])=[C:4]([NH:11][S:12]([CH3:15])(=[O:14])=[O:13])[CH:3]=1Komponenten
3
Versuchsvorschrift
Using 4-bromo-2-methanesulfonylaminobenzoic acid (964 mg) described in Preparation Example 225 and 1-(3,5-dimethylpyridin-2-yl)piperazine (629 mg) described in Preparation Example 79 and by the reaction and treatment in the same manner as in Preparation Example 111, the title compound (321 mg) was obtained.
Aufarbeitung
- customdescribed in Preparation Example 79 and by the reaction and treatment in the same manner as in Preparation Example 111